BIOMAT Database Logo BIOMAT Database Logo

Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. 2007

Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
Division of Surgical Oncology, Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.msabel@umich.edu <msabel@umich.edu>

BACKGROUND With the introduction of sentinel lymph node (SLN) biopsy for melanoma, inguinal lymph node dissections (ILND) are more commonly performed for microscopic disease than for clinically palpable disease. We sought to examine the effect this change has on the morbidity of the operation. METHODS A retrospective review was performed of all patients who underwent an ILND for melanoma between October 1997 and April, 2006. Clinical and pathologic data were collected and correlated by multivariate analysis with the incidence of a major wound complication. RESULTS We identified 212 patients, 132 who underwent an ILND for a positive SLN and 80 for clinically palpable disease. Age, sex, and body mass index (BMI) were similar in both groups. Patients with clinically palpable disease had a significantly greater number of involved nodes (3.0 vs 1.96, P = .0013), more often had >or=4 involved nodes (29% vs 9%, P < .001), and a greater incidence of extranodal extension (47% vs 5%, P < .001). Of the 212 patients, 41 (19%) had a significant wound complication. This complication was significantly higher among patients with clinical disease compared to patients with a positive SLN (28% vs 14%, P = .02). Only BMI (odds ratio of 1.1) and the indication for the procedure (odds ratio of 2.2) were independent predictors of a major wound complication. Lymphedema occurred in 30% of the patients and was only significantly associated with clinical disease (41% vs 24%, P = .025). With a median follow-up of 2 years, regional recurrence was not significantly greater in patients with clinically palpable disease (13% vs 9%, P = not significant [ns]), although this result was possibly due to the significantly greater rate of distant recurrence (49% vs 18%, P < .001) and death (48% vs 21%) in these patients. CONCLUSIONS Patients undergoing an ILND for a positive SLN have a significantly lower risk of postoperative complication or lymphedema than do patients undergoing ILND for clinically palpable disease. There is a benefit in regard to the morbidity of treatment in surgically staging melanoma patients by SLN biopsy and preventing ILND for palpable disease.

UI MeSH Term Description Entries
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008209 Lymphedema Edema due to obstruction of lymph vessels or disorders of the lymph nodes. Milroy's Disease,Congenital Familial Lymphedema,Congenital Hereditary Lymphedema,Early Onset Lymphedema,Hereditary Lymphedema,Hereditary Lymphedema 1,Hereditary Lymphedema Type I,Lymphedema, Early-Onset,Lymphedema, Hereditary, Ia,Milroy Disease,Nonne-Milroy Disease,Nonne-Milroy Lymphedema,Nonne-Milroy-Meige Disease,Primary Congenital Lymphedema,Congenital Hereditary Lymphedemas,Congenital Lymphedema, Primary,Congenital Lymphedemas, Primary,Early Onset Lymphedemas,Early-Onset Lymphedema,Early-Onset Lymphedemas,Hereditary Lymphedema 1s,Hereditary Lymphedema, Congenital,Hereditary Lymphedemas,Hereditary Lymphedemas, Congenital,Lymphedema, Congenital Hereditary,Lymphedema, Early Onset,Lymphedema, Hereditary,Lymphedema, Nonne-Milroy,Lymphedema, Primary Congenital,Lymphedemas,Lymphedemas, Congenital Hereditary,Lymphedemas, Early Onset,Lymphedemas, Early-Onset,Lymphedemas, Hereditary,Lymphedemas, Primary Congenital,Milroys Disease,Nonne Milroy Disease,Nonne Milroy Lymphedema,Nonne Milroy Meige Disease,Primary Congenital Lymphedemas
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010173 Palpation Application of fingers with light pressure to the surface of the body to determine consistence of parts beneath in physical diagnosis; includes palpation for determining the outlines of organs. Palpations
D005260 Female Females
D006119 Groin The external junctural region between the lower part of the abdomen and the thigh. Groins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma.
April 2019, Current oncology reports,
Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.
September 2018, Current treatment options in oncology,
Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
Sentinel lymph node biopsy and completion lymph node dissection in melanoma.
June 2021, Clinical advances in hematology & oncology : H&O,
Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma.
September 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
[Sentinel node biopsy and lymph node dissection in the era of new systemic therapies for malignant melanoma].
November 2019, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
Correction to: Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.
August 2019, Current treatment options in oncology,
Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
Sentinel Lymph Node Biopsy, Lymph Node Dissection, and Lymphedema Management Options in Melanoma.
October 2021, Clinics in plastic surgery,
Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
[Sentinel lymph node biopsy to select patients with melanoma for regional lymph node dissection].
March 1995, Nederlands tijdschrift voor geneeskunde,
Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.
May 2015, The Cochrane database of systematic reviews,
Michael S Sabel, and Kent A Griffith, and Alisha Arora, and Josef Shargorodsky, and Dan G Blazer, and Riley Rees, and Sandra L Wong, and Vincent M Cimmino, and Alfred E Chang
Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era.
September 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!